

INSTRUCTIONS FOR AUTHORS

PNEUMON is a peer reviewed, bilingual (Greek and English) journal published quarterly as the official scientific journal of the Hellenic Thoracic Society and the Hellenic Bronchologic Society. The Journal publishes original papers of international interest on laboratory and clinical research that are pertinent to lung biology and disease. Clinical and experimental work dealing with the whole field of pneumonology, including allied health, cell and molecular biology, epidemiology, immunology, pathology, pharmacology, physiology, intensive and critical care, paediatric respiratory medicine and thoracic surgery will be published. All manuscripts and correspondence are submitted **by e-mail** to the address: pneumon@hts.org.gr with a cover letter including the title of the paper, a statement that neither the article nor any part of its essential substance has been or will be published or submitted elsewhere that all authors have read and approved the text of the article and that, if considered for publication, they transfer the copyright to Journal.

Articles published in PNEUMON address topics related to pneumonology and critical care medicine in the following categories: 1) Editorials (usually after invitation, 2-4 pages), 2) Reviews (20-30 pages), 3) Basic and clinical research studies (20-25 pages), 4) Case reports (5-8 pages), 5) Special articles (8-10 pages), 6) Correspondence (no more than 500 words and 5 references).

Editorials, reviews and special articles are published following invitation by the Editorial Board. The Editorial Board reserves the right of publishing other types of papers as well. Papers submitted for publication will not be returned, irrespective of whether they are published or not. Published papers are a literary property of both the authors and the journal and their publication, in part or in whole, without written permission of the Editorial Board is prohibited.

Cover letter

Corresponding authors must provide a cover letter which includes statements concerning: (a) that the work has been seen and approved by all co-authors, (b) how the work is clinically relevant, and how it adds to existing research, (c) whether papers closely related to the submitted manuscript have been published or submitted for publication elsewhere and if so, the authors should provide details. Failure to provide a cover letter addressing each of the points above will result in the paper being returned to the author. The cover letter must be presented as a separate submission item.

Manuscripts containing original material are accepted for consideration if neither the article nor any part of its essential substance has been or will be published or submitted elsewhere. Copies of any closely re-

lated manuscripts must be submitted along with the manuscript. PNEUMON discourages the submission of more than one article dealing with related aspects of the same study. Authors should follow the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," published by the International Committee of Medical Journal Editors at <http://www.icmje.org>, and the Helsinki declaration (<http://www.wma.net/e/policy/b3.htm>).

Credit for **authorship** requires substantial contribution to (a) the concept and design or analysis and interpretation of the data, and (b) the drafting of the article or critical revision for important intellectual content.

Any change in authorship after submission must be approved in writing by all authors. All text, references, figure legends, and tables should be in one double-spaced electronic document (WORD doc or PDF).

Title page. The title page must contain the following information: a) the title (more than 10 words). If it is necessary the title can include a sub-title b) the full name, institutions, city and country for all co-authors c) up to 5 keywords or phrases suitable to use in an index d) the name, postal address, e-mail, telephone, and fax numbers of the corresponding author e) possible financial resources f) the current title g) the total number of words.

Abstract. An structured abstract should be provided of not more than 250 words. It should consist of four paragraphs, labelled Background, Methods, Results, and Conclusions. They should briefly describe, respectively, the problem being addressed in the study, how the study was performed, the most important results, and what the authors conclude from the results. Up to 5 key words should be added taken, from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list at <http://www.nlm.nih.gov/mesh/meshhome.html>.

Text. The paper should include the following sections:

Introduction

The rationale for the study should be summarised and relevant background material outlined. The Introduction should not contain either findings or conclusions.

Methods

Methods should be described in adequate detail to assure the reader as to how the results were obtained. The location (city, state, country) of a manufacturer listed in the text should be provided. Units should conform to SI conventions. Generic names of drugs should be used instead of trade names. Statistical methods should be meticulously described and referenced.

Results

Results should be presented in a logical order in the text, tables and figures. The authors should avoid repetitive presentation of the same data in different forms, especially between the text and tables and figures. The Results should not include material appropriate to the Discussion.

Discussion

The discussion should start by presenting the new and most interesting data of the work in relation to any hypotheses made in the Introduction. Any unexpected or contradictory results should be explained or defended, for example, evaluation of methodology and the relationship of new information to the existing knowledge in the topic. Speculation should be kept to a minimum. The results must not be simply reiterated. New research data should not appear in the Discussion. No specific refer once to figures and tables is made in the Discussion.

Acknowledgements

Acknowledge the persons who made a true contribution and who endorse the data and conclusions. Acknowledge any funding sources.

References

Only published works may be cited as references; manuscripts accepted but not yet published may be cited designating the accepting journal, followed by (in press), and providing copies of the in-press articles for reviewer inspection. References should be cited in the text with superscript numerals in the order that references are first cited. On the reference page, cited works in numerical order should be made of, in the Journal's style for references, abbreviating journal names as in *Index Medicus* (see: <http://www.nlm.nih.gov>) and listing all authors when there are six or fewer; when there are seven or more, list the first three, followed by "et al." The following are sample references:

• *Standard journal article*: Bouros D, Antoniou KM, Light RW. Intrapleural streptokinase for pleural infection. *BMJ* 2006; 332:133-4.

• *Books and other monographs*: Siafakas NM, Anthonisen N, Georgopoulos D. Acute exacerbations of COPD. Marcel Dekker, New York, 2004

• *Chapter in a book*: Kyriakou D, Alexandrakis M, Bouros D. Pleural effusions in blood diseases. *In*: Bouros D. (editor). *Pleural Disease*. Marcel Dekker, New York, 2004, pp. 621-638.

Numbered references to personal communications, unpublished data, or manuscripts either "in preparation" or "submitted for publication" are unacceptable. If essential, such material can be incorporated at the appropriate place in the text.

Tables. Double-space tables (including any footnotes) should be presented on separate pages providing a title for each.

Figures. Figures may be inserted in the text file or in a separate file (JPEG, TIFF, EPS). Legends for all figures should be included in the file with the text and should not appear on the figures. If photographs of patients are used, either they should not be identifiable or the photographs should be accompanied by written permission to use them.

Permission. The manuscript must be accompanied by copies of permission to reproduce previously published material (figures or tables); to use illustrations of, or report sensitive personal information about, identifiable persons; and to name persons in the Acknowledgments section.

Manuscripts concerning research supported in whole or in part by tobacco companies and associated institutes and organisations will not be considered for publication.

SUBMISSION:

Editor-in-Chief:

Professor Demosthenes Bouros MD, FCCP

PNEUMON Journal, Hospital for Diseases of the Chest "SOTIRIA",

152 Messogeion Ave, 11527, Athens, GREECE

Tel/Fax: +30-210-74.87.723

www.pneumon.org

www.hts.org.gr

e-mail: pneumon@hts.org.gr